News & Views
Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab)…
Read more
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product,…
Read more
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging…
Read more
With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in…
Read more
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art…
Read more
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron…
Read more
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate…
Read more
We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021….
Read more
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September…
Read more
Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual…
Read more